Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Weight-loss drugs that mimic the effect of regulatory hormones on appetite and energy balance often come with a few rather ...

Three dads share how their bodies and family relationships have changed since they began taking GLP-1 weight loss medications ...

Whether it's weird workout classes or wild exercise devices, the rise of Ozempic is supercharging America's desire for ...

The Shapiro administration's plan would limit Ozempic access under Medicaid to save costs. Not everyone is on board.

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

New Studio Opening June 6 to Meet Rising Demand for All-Encompassing Wellness and Weight Loss Offerings Lindora, a leading provider of medically guided weight loss and metabolic health solutions, is ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...